A EBITDA margin az China Health Group Inc. - 135.28%
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People's Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; post launch market research, medical, and medical market services; medical science liaisons; and other medical services. It also provides hospital management, medical tourism, and specialized hospital services, as well as Venturepharma cloud; and sells drug technologies. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.